Physician profile
John Jakob
NPI 1831394287
$1,827.56
in general payments reported to CMS, 2019-2025
18 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $70.91 · 2021: $11.92 · 2022: $151 · 2023: $197 · 2024: $77.69 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,117 · Food and Beverage: $249 · Education: $63.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,116.56 |
| Food and Beverage | $248.93 |
| Education | $63.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,135.53 | 2025 | |
| Merck Sharp & Dohme LLC | $116.70 | 2020-2024 | Keytruda, Reblozyl, Welireg |
| Novartis Pharmaceuticals Corporation | $91.33 | 2019-2022 | |
| Amgen INC. | $88.88 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $70.16 | 2020-2024 | |
| Emd Serono, INC. | $43.80 | 2023 | |
| Morphosys, US INC. | $41.14 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $40.98 | 2024-2025 | Opdivo |
| Daiichi Sankyo INC. | $32.02 | 2023 | Injectafer |
| Jazz Pharmaceuticals INC. | $31.61 | 2022-2023 | Zepzelca |
| Gilead Sciences, INC. | $26.41 | 2021-2024 | |
| Pfizer INC. | $18.54 | 2023 | |
| Celgene Corporation | $17.72 | 2019 | |
| Janssen Biotech, INC. | $17.14 | 2022 | |
| Abbvie INC. | $14.61 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $14.55 | 2022 | |
| Array Biopharma INC | $14.11 | 2022 | |
| Lilly USA, LLC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jakob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.